Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease

On page 275 of this article, the Conflict of Interest statement was incorrect. The authors would like to correct the Conflict of Interest statement as follows. Before: The authors have no financial conflicts of interest. After: Masaaki Mori has received consulting fees from Daiichi Sankyo, Ltd. and Taisho Pharmaceutical, Co., Ltd.; and belongs to an institution that has received funding from Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corporation, UCB Japan Co., Ltd., Nippon Kayaku Co., Ltd., CSL Behring Corporate, Asahi Kasei Pharma Corporation, AbbVie GK, and Japan Blood Products Organization. Yoshiko Nakayama has received lecture fees from AstraZeneca. Shigeo Nishimata, Tadafumi Yokoyama, Ryo Matsuoka, Reiko Hatori, Masaki Shimizu, Yuri Etani, and Tsuyoshi Sogo have no conflicts of interest to disclose. Katsuhiro Arai has received payments or honoraria from Takeda Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd.; and belongs to an institution that has received grants or contracts from AstraZeneca, Takeda Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd.; and consulting fees from EA Pharma Co., Ltd. Tomoko Ishizu, Masahiro Nii, and Ryosuke Nakashima are employees of AstraZeneca and hold stock options in AstraZeneca. Toshiaki Shimizu has received research grants from JCR Pharmaceuticals Co., Ltd. and The Food Science Institute Foundation (Ryoshoku-kenkyukai; Tokyo, Japan). The authors would like to apologise for any inconvenience caused.